Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3261274 | 0.79 | — | — | |
| SCHEMBL3261231 | 0.77 | SLC22A2 (0.34) | GPR3HTR2ASLC22A2SLC22A3 | |
| Hydrochloric Acid SCHEMBL3264206 | 0.76 | KDM4E (0.35) | HTR2A | |
| Hydrochloric Acid SCHEMBL3261953 | 0.76 | HTR2A (0.35) | GPR3HTR2A | |
| Hydrochloric Acid SCHEMBL3260592 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL3260699 | 0.74 | SIGMAR1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL3261813 | 0.74 | GPR3 (0.31) | GPR3HTR2A | |
| SCHEMBL10455243 | 0.70 | HTR2A (0.45) | GPR3HTR2ASLC22A2SLC22A3 | |
| Hydrochloric Acid SCHEMBL3258008 | 0.70 | GPR3 (0.35) | GPR3HTR2A | |
| Hydrochloric Acid SCHEMBL3259562 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678784-B2 | Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-16 | — | — | US | claimed |
| US-20080139523-A1 | OXIME-CONTAINING MACROCYCLIC ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | claimed |
| US-7678784-B2 | Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7671226-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7439379-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20080139523-A1 | OXIME-CONTAINING MACROCYCLIC ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139523-A1 | OXIME-CONTAINING MACROCYCLIC ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BACE1, APP, BACE2 | GPR3 832/4885HTR2A 1960/4885SLC22A2 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.